598 related articles for article (PubMed ID: 30463416)
1. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
[TBL] [Abstract][Full Text] [Related]
2. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the treatment of psoriasis: role of biologic agents.
Rich SJ; Bello-Quintero CE
J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
[TBL] [Abstract][Full Text] [Related]
4. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severe psoriasis in children: recommendations of an Italian expert group.
Fortina AB; Bardazzi F; Berti S; Carnevale C; Di Lernia V; El Hachem M; Neri I; Gelmetti CM; Lora V; Mazzatenta C; Milioto M; Moretta G; Patrizi A; Peris K; Villani A
Eur J Pediatr; 2017 Oct; 176(10):1339-1354. PubMed ID: 28836064
[TBL] [Abstract][Full Text] [Related]
6. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
7. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
[TBL] [Abstract][Full Text] [Related]
8. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
[TBL] [Abstract][Full Text] [Related]
9. Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review.
Ghamrawi RI; Ghiam N; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1252-1256. PubMed ID: 32962478
[TBL] [Abstract][Full Text] [Related]
10. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Carpentieri A; Pacello L; De Marco IM; Loiacono A; Picconi O; Loconsole F
J Dermatolog Treat; 2016 Oct; 27(5):399-405. PubMed ID: 26822691
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
15. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
17. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
18. Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO - Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society).
Kogan N; Raimondo N; Gusis SE; Izcovich A; Abarca Duran JA; Barahona-Torres L; Blanco O; Quintana GB; Briones MC; Castro C; Castro Vargas EG; Criniti J; Diez de Medina JC; Franco M; Gómez M; Levrero VP; Martínez López JE; Valenzuela F
Int J Dermatol; 2019 Aug; 58 Suppl 1():4-28. PubMed ID: 31282026
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
20. Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.
Ighani A; Yu AM; Sandhu VK; Barankin B; Manolson MF
J Cutan Med Surg; 2019; 23(2):148-156. PubMed ID: 30801221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
